- Q1 2024 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$1.09 (-9.17%)Earnings
- Q4 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 21, 2024$1.31 (+28.43%)Earnings
- Q3 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$0.79 (+6.68%)Earnings
- X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- X4 Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 10, 2023$1.05 (-35.98%)Earnings
- X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call TranscriptMay 16, 2023
- Q1 2023 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023$1.54 (+4.05%)Earnings
- Q4 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 21, 2023$0.8954 (+0.97%)Earnings
- X4 Pharmaceuticals Inc To Discuss Key Top-Line 4WHIM Trial Results TranscriptNov 29, 2022
- X4 Pharmaceuticals Inc at Stifel Healthcare Conference TranscriptNov 15, 2022
- Q3 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022$1.89 (-3.57%)Earnings
- X4 Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 11, 2022
- Q2 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2022$1.27 (-1.55%)Earnings
- Q1 2022 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022$1.04 (-0.95%)Earnings
- X4 Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 17, 2022$1.77 (-10.61%)Earnings
- X4 Pharmaceuticals Inc at B Riley Oncology Conference (Virtual) TranscriptJan 28, 2022
- Q3 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 04, 2021$5.15 (-8.04%)Earnings
- X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2021$5.66 (-4.55%)Earnings
- Q1 2021 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2021$8.12 (+1.50%)Earnings
- Q4 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 04, 2021$9.18 (-5.75%)Earnings
- X4 Pharmaceuticals Inc Dr. Ragan Discusses X4's Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases TranscriptDec 23, 2020
- Q3 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$6.01 (-6.68%)Earnings
- Q2 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptJul 30, 2020$7.73 (-3.50%)Earnings
- X4 Pharmaceuticals Inc Post-EHA Corporate Update TranscriptJun 12, 2020
- Q1 2020 X4 Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$8.56 (-4.89%)Earnings
- X4 Pharmaceuticals Inc Virtual Analyst Day - A Deep Dive into WHIM Syndrome TranscriptApr 07, 2020
- Q4 2019 X4 Pharmaceuticals Inc Earnings Call TranscriptMar 12, 2020$8.13 (-5.24%)Earnings
- Q3 2019 X4 Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019$13.41 (+3.79%)Earnings
X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us on day four of the virtual Cantor Healthcare Conference. My name is Emma Nealon, and I am one of the small/mid-cap biotech analysts here Cantor. It is my pleasure to be hosting X4 Therapeutics this morning for a fireside chat. And joining us today from X4 is CEO, Paula Ragan.
So let's start with a brief overview of X4 and your lead asset, mavorixafor. Where did the asset come from? And maybe walk us through the mechanism of action.
Sure. Good morning, Emma, and thanks so much for hosting us at the Cantor conference. We appreciate it. So you know we are really excited about our lead asset, mavorixafor. It is a drug that impacts and modulates the immune system, which you can appreciate has tremendous potential as we think about it here, and certainly in the last year and a half that we've all lived through. In terms of what CXCR4 -- the target -- it does in the healthy state is it helps regulate the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)